SETTING: The Philippines, one of the high tuberculosis (TB) burden countries. OBJECTIVE: To determine the prevalence of anti-tuberculosis drug resistance in the first nationwide systematic survey. DESIGN: A population-proportionate cluster sampling method was employed. Smear-positive pulmonary TB patients aged > or = 15 years were eligible. Drug susceptibility testing was performed against four first-line drugs, i.e., isoniazid, rifampicin, ethambutol and streptomycin. RESULTS: A total of 1091 patients were enrolled during a 17-month period starting in June 2003, of whom 935 (85.7%) were new cases and 121 (11.1%) previously treated cases. Resistance to any of the four drugs was seen in 20.4% (95%CI 18.1-22.9) of new cases, in 38.8% (95%CI 27.8-51.1) of previously treated cases and in 22.1% (19.7-24.9) of both new and previously treated cases combined. The prevalence of multidrug resistance was respectively 3.8% (95%CI 2.6-5.5), 20.9% (95%CI 13.0-32.0) and 5.7% (95%CI 4.3-7.5). The prevalence of drug resistance among new cases was higher than the global average and it was widespread throughout the country. CONCLUSION: Confronted with the high prevalence of drug resistance, current efforts by the government to ensure better quality treatment programme should be strengthened.
SETTING: The Philippines, one of the high tuberculosis (TB) burden countries. OBJECTIVE: To determine the prevalence of anti-tuberculosis drug resistance in the first nationwide systematic survey. DESIGN: A population-proportionate cluster sampling method was employed. Smear-positive pulmonary TB patients aged > or = 15 years were eligible. Drug susceptibility testing was performed against four first-line drugs, i.e., isoniazid, rifampicin, ethambutol and streptomycin. RESULTS: A total of 1091 patients were enrolled during a 17-month period starting in June 2003, of whom 935 (85.7%) were new cases and 121 (11.1%) previously treated cases. Resistance to any of the four drugs was seen in 20.4% (95%CI 18.1-22.9) of new cases, in 38.8% (95%CI 27.8-51.1) of previously treated cases and in 22.1% (19.7-24.9) of both new and previously treated cases combined. The prevalence of multidrug resistance was respectively 3.8% (95%CI 2.6-5.5), 20.9% (95%CI 13.0-32.0) and 5.7% (95%CI 4.3-7.5). The prevalence of drug resistance among new cases was higher than the global average and it was widespread throughout the country. CONCLUSION: Confronted with the high prevalence of drug resistance, current efforts by the government to ensure better quality treatment programme should be strengthened.
Authors: R S Garfein; D G Catanzaro; T C Rodwell; E Avalos; R L Jackson; J Kaping; H Evasco; C Rodrigues; V Crudu; S-Y G Lin; E Groessl; E Groessel; N Hillery; A Trollip; T Ganiats; T C Victor; K Eisenach; F Valafar; J Channick; L Qian; A Catanzaro Journal: Int J Tuberc Lung Dis Date: 2015-04 Impact factor: 2.373
Authors: Catharina C Boehme; Mark P Nicol; Pamela Nabeta; Joy S Michael; Eduardo Gotuzzo; Rasim Tahirli; Ma Tarcela Gler; Robert Blakemore; William Worodria; Christen Gray; Laurence Huang; Tatiana Caceres; Rafail Mehdiyev; Lawrence Raymond; Andrew Whitelaw; Kalaiselvan Sagadevan; Heather Alexander; Heidi Albert; Frank Cobelens; Helen Cox; David Alland; Mark D Perkins Journal: Lancet Date: 2011-04-18 Impact factor: 79.321
Authors: Malancha Karmakar; Romain Ragonnet; David B Ascher; James M Trauer; Justin T Denholm Journal: BMC Infect Dis Date: 2022-01-24 Impact factor: 3.090